| abstract |
The present invention has a cannabinoid receptor agonistic action, Formula (I): Wherein R 1 is an optionally substituted C1-C8 alkyl, etc .; R 2 is a C1-C6 alkyl; R 3 is a C1-C6 alkyl, etc .; or R 2 and R 3 are substituted together May form a 5- to 10-membered non-aromatic carbocyclic ring; R 4 represents a hydrogen atom or the like; G is the formula: (In the formula, R 5 is a hydrogen atom or the like; X 1 is a single bond or the like; X 2 may be one or two of —O— or —N (R 6 ) — (R 6 is a hydrogen atom or the like). A compound represented by a group selected from: a group represented by: a C1-C8 alkylene which may be substituted, etc .; X 3 is a single bond, etc .; Y is —O—, etc .; Z is a hydrogen atom, etc. A pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutical composition containing the compound as an active ingredient, an atopic dermatitis therapeutic agent and an anti-pruritic agent, particularly an oral anti-pruritic agent and an external anti-pruritic agent. provide. |